{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-122872","form_type":"8-K","ticker":"RANI","cik":"0001856725","company_name":"Rani Therapeutics Holdings, Inc.","filed_at":"2025-05-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.199944+00:00","generated_at":"2026-05-21T00:29:10.269153+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Rani Therapeutics induces warrant exercise by Armistice, receives ~$4.3M","bullets":["Gross proceeds of ~$4.3M from cash exercise of Series B & C warrants at reduced exercise price of $0.65/sh.","Issues new Series D warrant for 13,160,172 shares at $0.65/sh, 5-year term, subject to stockholder approval.","Company must file resale registration statement for Series D shares within 45 days; seeks Nasdaq approval.","Maxim Group receives 5.25% cash fee on gross proceeds as financial advisor.","Proceeds to be used for working capital and general corporate purposes via Rani LLC."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-122872","json":"https://secwatch.observer/filing/0001193125-25-122872.json","markdown":"https://secwatch.observer/filing/0001193125-25-122872.md","text":"https://secwatch.observer/filing/0001193125-25-122872.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1856725/000119312525122872/0001193125-25-122872-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1856725/000119312525122872/d945177d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T00:29:10.269153+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}